BVT Call 160 NVO 19.12.2025/ DE000VD9V248 /
16/10/2024 19:56:52 | Chg.-0.010 | Bid21:58:24 | Ask21:58:24 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.290EUR | -3.33% | - Bid Size: - |
- Ask Size: - |
Novo Nordisk | 160.00 USD | 19/12/2025 | Call |
Newsfile Corp
28/08
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
28/08
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
28/08
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
GlobeNewswire
27/08
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
26/08
Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amy...
GlobeNewswire
21/08
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
GlobeNewswire
14/08
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. Georg...
GlobeNewswire
06/08
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
01/08
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Dire...
GlobeNewswire
11/07
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansio...
GlobeNewswire
11/07
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...
GlobeNewswire
11/07
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...